Cercar
01/01/2022
Noninvasive Respiratory Support for Adults with Acute Respiratory Failure
Munshi L., Mancebo J., Brochard L.J.. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(18)DOI:10.1056/NEJMra2204556. PMID:36322846. IF:158.500(Q1/1D).
01/01/2022
Mechanical ventilation in Spain, 1998-2016: changes in the disconnection of mechanical ventilation
Frutos-Vivar F., Peñuelas O., Muriel A., Mancebo J., García-Jiménez A., de Pablo R., Valledor M., Ferrer M., León M., Quiroga J.M., Temprano S., Vallverdú I., Fernández R., Gordo F., Anzueto A., Esteban A.. Mechanical ventilation in Spain, 1998-2016: changes in the disconnection of mechanical ventilation. Medicina Intensiva. 2022; 46(7)DOI:10.1016/j.medin.2021.04.005. PMID:34092422. IF:3.000(Q3/7D).
01/01/2022
Tabún, sarín, somán, VX y novichoks: agentes neurotóxicos organofosforados con finalidad bélica o criminal
Belvís R., Morollón N., Cortés-Vicente E., Morán I.. Tabún, sarín, somán, VX y novichoks: agentes neurotóxicos organofosforados con finalidad bélica o criminal. Kranion. 2022; 17(2)DOI:10.24875/KRANION.M22000030. PMID:. IF:(Q/D).
01/01/2022
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Chastre J., François B., Bourgeois M., Komnos A., Ferrer R., Rahav G., De Schryver N., Lepape A., Koksal I., Luyt C.-E., Sánchez-García M., Torres A., Eggimann P., Koulenti D., Holland T.L., Ali O., Shoemaker K., Ren P., Sauser J., Ruzin A., Tabor D.E., Akhgar A., Wu Y., Jiang Y., DiGiandomenico A., Colbert S., Vandamme D., Coenjaerts F., Malhotra-Kumar S., Timbermont L., Oliver A., Barraud O., Bellamy T., Bonten M., Goossens H., Reisner C., Esser M.T., Jafri H.S., Joannidis M., Klimscha W., De Waele E., Devriendt J., Huberlant V., Depuydt P., Van Boxstael S., Peric M., Kopic J., Hanauer M., Hruby T., Sramek V., Svoboda P., Vymazal T., Novacek M., Annane D., Mira J.-P., Souweine B., Dequin P.-F., Meziani F., Stephan F., Nseir S., Gibot S., Schwebel C., Plantefeve G., Diehl J.-L., Richard C., Lamer C., Klouche K., Jaber S., Zakynthinos E., Filntisis G., Zakynthinos S., Koutsoukou A., Saroglou G., Nikolaou C., Vlachogianni G., Pnevmatikos I., Mandragos K., Kremer I., Rozgonyi Z.D., Marjanek Z., Martin-Loeches I., Singer P., Van Heerden V., Carmeli Y., Povoa P., Seoane A.A., Moura P., Gonzalez F., Ramirez P., Marti A.T., Roca R.F., Oteiza L., Escudero D., Piacentini E., Vera P., Tamayo L., Gallego M.A.G., Canas B.S., Figueira I., Leon R., Korten V., Akova M., Wyncoll D., Whitehouse T., Hopkins P., Sim M., Golan Y., Zervos M., Vazquez J., Cherabuddi K., Smulian G., Rouphael N., Welker J., Sims M., Van Duin D., McCarthy T., Polk C.. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. CRITICAL CARE. 2022; 26(1)DOI:10.1186/s13054-022-04204-9. PMID:36380312. IF:15.100(Q1/2D).